Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
40.56
+0.17 (+0.42%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small
Via
Benzinga
Exposures
Product Safety
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
The real competitive battle is about to begin, and it will last a long time.
Via
The Motley Fool
BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake
November 07, 2023
The company's recently FDA-approved gene therapy is struggling to gain traction.
Via
Investor's Business Daily
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
November 02, 2023
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate
Via
Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...
Via
Benzinga
Exposures
Product Safety
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
The U.S.
Via
Benzinga
Exposures
Product Safety
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
October 28, 2023
The three companies are spending big on IBD therapies.
Via
The Motley Fool
It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy
October 24, 2023
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
Via
The Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.
Via
InvestorPlace
Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space
October 23, 2023
Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.
Via
Investor's Business Daily
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
October 23, 2023
Roche Holding AG (OTC: RHHBY) inked a deal to acquire
Via
Benzinga
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
October 21, 2023
The venerable pharmaceutical companies' shares have slumped this year.
Via
The Motley Fool
Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance
October 19, 2023
The company's third-quarter sales also declined and came in light.
Via
Investor's Business Daily
Exposures
COVID-19
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
October 19, 2023
Roche Holdings AG's (OTC: RHHBY) nine months
Via
Benzinga
Exposures
COVID-19
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
October 17, 2023
Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:
Via
Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
October 17, 2023
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda for resectable (tumors ≥4 centimeters [cm] or node-positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing...
Via
Benzinga
Exposures
Product Safety
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
October 16, 2023
Prothena Corporation plc (NASDAQ: PRTA) is reportedly talking to advisors, potentially preparing for a sale.
Via
Benzinga
AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points
October 14, 2023
Broadcom and Arista lead five stocks sporting a flat base.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
TPST Stock: 7 Things to Know About Tempest Therapeutics
October 11, 2023
Are you curious about the recent surge from Tempest Therapeutics? Here's a closer look at this company and at TPST stock.
Via
InvestorPlace
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...
Via
Benzinga
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update
October 04, 2023
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug c
Via
Benzinga
Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich
October 03, 2023
Are you looking to invest in biotechnology breakthroughs? Here are three biotech stocks that could make early investors rich.
Via
InvestorPlace
2 Cathie Wood Stocks That Could Deliver Exponential Returns
October 02, 2023
These two cutting-edge healthcare companies could be significantly undervalued right now.
Via
The Motley Fool
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY
Via
Benzinga
Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder
September 26, 2023
IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.
Via
Investor's Business Daily
AI To Revolutionize Clinical Trials And Diagnostics
September 22, 2023
With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
September 21, 2023
In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.
Via
Benzinga
Exposures
COVID-19
Buy List Alert: 3 Pharma Stocks with Positive Trial Updates
September 13, 2023
These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.
Via
InvestorPlace
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
September 12, 2023
Find out why analysts have such high expectations for these stocks.
Via
The Motley Fool
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
September 11, 2023
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care....
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.